Beyond Natural Targeting Limits: Engineered Serine Integrases Advance Large DNA Knock-in

Engineered integrases for large DNA integration

CRISPR-Cas9-mediated gene knock-in primarily relies on homology-directed repair (HDR). However, this approach has clear limitations when inserting large DNA fragments: efficiency is constrained by the cell cycle, large donor templates are difficult to deliver, and double-strand breaks may cause genomic instability.

Researchers have therefore been exploring new strategies that can write DNA precisely without relying on conventional DNA repair pathways.

Nature Biotechnology recently published a research article alongside a related commentary highlighting advances in engineered recombinases for the precise integration of large DNA sequences.

In the study, a Sangamo Therapeutics research team developed MINT (Modular Integrase), an engineered serine integrase platform that retargets Bxb1 integrase to enable precise, site-specific integration of large DNA sequences in human cells.

The Potential and Limitations of Engineered Serine Integrases

Serine integrases are a class of recombinases that naturally catalyze DNA integration.

Unlike editing approaches that depend on DNA break repair, serine integrases can directly mediate site-specific DNA insertion, giving them distinct advantages for integrating large DNA payloads.

Among them, the bacteriophage-derived Bxb1 integrase has long been considered a promising candidate for genome-writing tools because of its high integration efficiency.

Natural Bxb1 integrase, however, has a critical limitation: it recognizes only specific attB and attP sequences, which are not naturally present in the human genome.

To use integrases in human cells, researchers have traditionally had to install a recognizable landing-pad sequence at the target locus before integrating the DNA cargo. This additional step increases system complexity and limits the technology's use in endogenous-locus editing and cell therapy.

MINT Enables Large DNA Integration

To overcome the limited targeting range of natural integrases, the Sangamo team developed the MINT platform.

Using structural modeling, directed evolution, and a human-cell screening system, the researchers redesigned Bxb1 integrase to recognize selected regions of the human genome. This enables precise integration of large DNA sequences without first installing an exogenous recognition site.

key advance is the conversion of an integrase that naturally recognizes only fixed att sites into a human genome-editing tool that can be retargeted as needed.

The team further evaluated the integration efficiency of MINT in human cells.

By combining activity-enhancing Bxb1 variants with zinc-finger DNA-binding domains, the researchers achieved precise integration at multiple genomic loci in K562 cells:

· 29% at the AAVS1 locus;

· 35% at the TRAC locus.

More importantly, the team demonstrated the system's translational potential in primary human T cells, achieving 29% integration of a GFP reporter at the TRAC locus.

This result is directly relevant to gene insertion in T-cell therapies such as CAR-T. Precisely integrating a therapeutic gene into a defined genomic locus could improve the consistency and safety of engineered cell products.

Outlook and Remaining Challenges

As genome editing expands into more advanced applications, precise large DNA integration is becoming a major area of competition among emerging technology platforms.

Alongside serine integrases, CRISPR-associated transposases (CASTs), bridge RNA-guided recombination systems, and prime editing-derived technologies are also advancing.

Earlier, Durrant and colleagues systematically screened recombinase families for large-fragment integration into the human genome, laying important groundwork for the engineering of Bxb1 and related integrases.

The accompanying Nature Biotechnology commentary likewise noted that retargeted recombinases are emerging as a new solution for precise insertion of large DNA sequences.

The future of genome editing is unlikely to be dominated by a single technology. Instead, a diverse toolkit may emerge to meet different application needs. Higher efficiency, larger payload capacity, and more precise targeting will be central to the next stage of translation.

EDITGENE continues to optimize gene knock-in technologies through its proprietary FLASH-KI platform, providing efficient and precise solutions for targeted sequence insertion. The platform supports stable cell line generation, functional gene introduction, and the development of complex genetically engineered models for disease mechanism studies, drug screening, and cell therapy research.

References

[1] Fauser, F., Arangundy-Franklin, S., et al. Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells. 2026.

[2] Palmgren, G. Retargeted Serine Integrases Enable Precise Large-Gene Insertion. 2026.

[3] Sangamo Therapeutics. Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing. 2024.

[4] Sangamo Therapeutics. Form 10-K (FY2025). 2026.

[5] Sangamo Therapeutics. Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders. 2026.